Scientists have developed new method of cancer immunotherapy

A new generation of cancer immunotherapy has been successful, and this therapy acts on the adaptive immune system, that is, foreign and diseased cells to accurately attack the specialized cells. The other arm of the immune system, known as innate immunity, is not idle in this battle. More research involving in recombinant dog proteins should be conducted.

In a new study in the journal Nature, scientists at the Dana-Farber Cancer Institute report that compounds that can reverse innate immune system cells - transforming them from tumor promoters into tumor antagonists - cause breast cancer in mice to contract withdrawal transfer. When combined with chemotherapy or another immunotherapy, the new compound significantly prolongs the tumor remission. The authors suggest that these findings suggest a way to make a complete composition of the immune system affecting human cancer.

"Most of the current forms of cancer immunotherapy are "taught" by attacking tumor cells or eliminating the barriers to such attacks, affecting the behavior of T cells - leukocytes are part of the adaptive immune system," Guerriero said. "This strategy has been effective against several types of cancer, but usually only a fraction of patients benefit. We hope to see the use of the immune system to produce better results.

The newly-studied target is innate immune system cells called tumor-associated macrophages (TAM). They are usually deeply embedded in the tumor, but they are part of the immune system - the body against the disease defense system - they often promote tumor growth. In this way, they respond to the clues of the tumor itself.

The role of macrophages - both protective and destructive - depends on signals from their environment. In wound healing, for example, macrophages regulate the components of the immune system, removing damaged tissues and restoring affected areas. Tumor macrophages try to hijack these.

In previous studies, scientists from Dana-Farber and colleagues showed that a compound called TMP195 could transform TAMs from helping tumor growth to attacking them. TMP195 converts macrophage responses by altering the genetic activity within TAMs.

In this study, TMP195 significantly reduced the rate of tumor growth in breast cancer mice. They followed the combination of TMP195 with various chemotherapy regimens and an immunotherapy form called T cell checkpoint blockade. In both cases, the combination produces a longer remission of breast cancer than the TMP195 alone. Flarebio provides you with superior recombinant proteins including recombinant Itgb5.